

Reig Jofre, Internationalization of Spanish Healthcare Activity Award



Alex García Reig, Vice president of Reig Jofre

- Reig Jofre received recognition for its 20 years of internationalization in the V Edition of the New Medical Economics Awards, a digital publication specialized in the world of health management and patient experience

Barcelona (Spain), November 22, 2019, Pharmaceutical company Reig Jofre yesterday received the **Prize for the internationalization of Spanish healthcare activity** in the V Edition of the New Medical Economics Awards, a digital publication specialized in the world of healthcare management and patient experience.

This award recognizes the 20 years of internationalization of Reig Jofre's healthcare activity, in which it has gone from being a purely national company to being present in more than 70 countries thanks to the quality in its products development and in its customer service.

Reig Jofre's commitment to internationalization has been reflected in its ambitious investment plans. In 2018, the extension of the Toledo plant specialized in antibiotics to cover the needs of the national, European and Asian markets was completed. In mid-2018, the plan to expand the Barcelona plant specialized in pharmaceutical technologies for the production of sterile and lyophilized injectables for the national hospital market and European, Asian and African markets began. Recently, the investment to be undertaken at the Swedish plant for the exclusive manufacture of LECIGON® in Europe was announced, a drug indicated in the treatment of advanced Parkinson's disease.

Currently, 60% of sales come from international business, thanks to the direct commercial presence in 7 countries in Europe and Southeast Asia and through its network of more than 130 business partners in the rest of the markets.



About Reig Jofre

Founded in 1929 in Barcelona, Reig Jofre is a pharmaceutical company listed on the Spanish Stock Exchange's continuous market and dedicated to the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre structures its product development activity in three business areas: pharmaceutical technologies specialized in the development and manufacture of sterile and lyophilized injectable pharmaceutical products, as well as antibiotics derived from penicillin. Specialty products focused on the research, development, manufacture and commercialization of specialties in, above all, the areas of (i) skin, hair and nail health, (ii) joint health and pain, and (iii) women's health, And Consumer Healthcare, of which special mention may be made of the line of nutritional supplements, which are marketed under the brand Forté Pharma mostly in France, Belgium, Spain and Portugal, as well as other OTC products. Reig Jofre has more than 1000 employees, 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and more than 130 business partners in 70 countries around the world. The company closed 2018 with a turnover of 181 million euros. Reig Jofre is quoted on the Spanish stock exchange's continuous market under the ticker RJF. Share capital: 76,062,457 shares

For more information

Inma Santa-Pau - Head of Communication and Investor Relations
Tel. (+34) 935 450 078 - inma.santapau@reigjofre.com
www.reigjofre.com